Vivani Medical Inc (VANI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.49+7.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VANI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 357.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VANI — earnings in line
Dated 2026-08-13
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by reference in such a filing.
Why it matters: Keeping cash reserves is important for trials and operations. A strong cash position helps stability.
Watch forVivani has more than $20 million in cash. This shows a strong position.
Also watch forVivani has less than $15 million in cash. This raises concerns about funding.
Why it matters: Lower operating losses show better cost control and how well the company runs.
Supportive ifOperating losses decrease from -$6.82M in Q1 2026 to less than -$6M in Q2 2026.
Worry ifOperating losses remain at or worsen from -$6.82M in Q1 2026.
Why it matters: The merger will create Cortigent as a new public company. Vivani can focus on its drugs.
Supportive ifThe merger with ClearOne is done. Cortigent starts trading as a public company.
Worry ifThe merger is delayed or fails to close due to regulatory or financial issues.
Why it matters: Higher cash burn could signal financial strain and impact the company's runway through mid-2027.
Worry ifCash burn remains at or below $6.7 million for Q2 2026.
Less concerning ifCash burn exceeds $6.7 million in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $670 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,984 loss on $10,000 · 49.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This partnership may prove Vivani's technology. It could help them reach more customers.
Supportive ifNovo Nordisk gives good feedback or plans to work more on NPM-139.
Worry ifNovo Nordisk has concerns or stops looking at NPM-139.
Why it matters: Starting the SLIM-1 trial is key for Vivani's semaglutide implant. It shows progress in their drug development.
Supportive ifThe SLIM-1 trial officially starts as planned in mid-2026.
Worry ifThe trial does not start by mid-2026 or faces delays.
Why it matters: Results from this trial will show how well the NPM-139 implant works. Positive results could lead to a Phase 2 trial in 2027.
Supportive ifThe SLIM-1 trial shows good weight loss and safety results.
Worry ifThe data shows no weight loss and no safety issues.
Why it matters: This merger will spin off Cortigent as a separate company. It could help Vivani focus on its core drug implant business.
Supportive ifCortigent finishes the merger and starts trading as CRGT.
Worry ifThe merger faces delays or fails to close as planned.
Why it matters: Good Phase 1 results can improve the product lineup and attract more investor interest.
Supportive ifA press release confirming positive results from the NPM-139 Phase 1 trial by December 2026.
Worry ifNo results released by year-end or results are negative.
Why it matters: Maintaining cash reserves is crucial for funding ongoing operations and clinical trials. A strong cash position supports growth.
Supportive ifVivani has over $20 million in cash. This shows they have a strong future.
Worry ifCash reserves fall below $15 million. This raises worries about future funding.